Everything below concerns freeze-thaw cycle. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-07-24. Numbers and descriptions here follow the published literature rather than marketing material.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
Storage recommendations for SR9009 reference material typically specify a freezer at -20 °C or lower, with protection from moisture and light. Repeated freeze-thaw cycles can degrade small molecules and introduce variability. Stock solutions in dimethyl sulfoxide are often aliquoted to avoid repeated handling. Stability studies may examine degradation under heat, humidity, and light exposure. The compound's thiophene and nitro groups can participate in reactions that alter analytical signals over time, so such changes affect quantitative results.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
== Studies and research == A number of studies have been issued in regard to chocolate milk nutrition. A 2005 study by the New York City Department of Education found that by removing whole milk and replacing it with low-fat or fat-free chocolate milk, students were served an estimated 5,960 fewer calories and 619 fewer grams of fat per year. However, more recent studies show that fat-free and low-fat milk may actually increase body fat and contribute to obesity. Whole milk may in fact be healthier for obese children than low-fat or non-fat milk. An April 2007 study from Loughborough University indicated that low-fat milk was an effective rehydration drink. A November 2009 study conducted by scientists in Barcelona, Spain, suggests that regularly consuming skimmed milk with cocoa rich in flavonoids may reduce inflammation and slow or prevent the development of atherosclerosis. The study notes that its effects are not as pronounced as seen in consumption of red wine. However, in a single serving of cocoa, other researchers found 611 milligrams of gallic acid equivalents (GAE) and 564 milligrams of epicatechin equivalents (ECE), compared with 340 milligrams of GAE and 163 milligrams of ECE in red wine, and 165 milligrams of GAE and 47 milligrams of ECE in green tea. A study published in 2009 compared chocolate milk to a commercial recovery beverage (matched for carbohydrate and protein content) administered to cyclists after intense workouts.
A member of Parliament is a member of either of the two houses of the Pakistani Parliament: the National Assembly of Pakistan and Senate of Pakistan. The National Assembly of Pakistan has a total of 342 members, of whom 272 are directly elected, and 70 seats are reserved for women and minorities. A member of the National Assembly of Pakistan (MNA) has a tenure of five years. On the other hand, there are 96 members of the Senate of Pakistan, in which all four provinces are represented by 23 senators regardless of population, while the Islamabad Capital Territory is represented by four senators. A member of the Senate of Pakistan (a senator) has a tenure of six years.
A reduced lumen diameter consequently elevates the blood pressure within the arterioles. Conversely, decreased sympathetic activity within the vasomotor nerves causes vasodilation of the vessels thereby decreasing blood pressure.
Sources: en.wikipedia.org
Wolverine is killed again, along with Nightcrawler and others. However, he, along with the other X-Men who have been recently killed, are then resurrected in the Arbor Magus' hatchery on the Pacific island of Krakoa using a new 48 hour cloning process. In this new era, the X-Men have learned how to resurrect any mutant who has died. Wolverine enters into a violent conflict with Beast, who has become aggressive and paranoid in his defense of Krakoa.
Stanley (also known as Port Stanley) is the capital city of the Falkland Islands. It is located on the island of East Falkland, on a north-facing slope in one of the wettest parts of the islands. At the 2021 census, the city had a population of 2,974, accounting for 81% of the entire population of the Falkland Islands, which was 3,662 on Census Day – 10 October 2021. Stanley is represented by five of the eight elected members of the Legislative Assembly of the Falkland Islands: Stacy Bragger, Barry Elsby, Mark Pollard, Roger Spink, and Leona Vidal Roberts. An elected Town Council of Stanley existed from 1948 to 1973. On 14 June 2022, during the Platinum Jubilee Civic Honours, Stanley received letters patent, formally awarding it city status. It is the southernmost capital of a self-governing territory or state.
One way is to fuse modular binding sites (e.g., MS2 RNA tagging system, or RIDD-RIAD dock-and-lock system) to the phase-separating domain (e.g., synthetic RNA repeat, or IDP) that recruit "solute" or "client" of interest. Such a modular design enables engineering, optimization, and reusability of each fusion molecule, thus commonly applied in synthetic biology and metabolic engineering. Moreover, by applying a relatively slower binding system (e.g., split GFP), the recruitment of target into synthetic condensate can be fine-tuned by growth and division rates of the living cells. Another way to gain temporal control over the formation and dissolution of biomolecular condensates is by using optogenetic tools. Several different systems have been developed which allow for control of condensate formation and dissolution which rely on chimeric protein expression, and light or small molecule activation. In one system, proteins are expressed in a cell which contain light-activated oligomerization domains fused to IDRs. Upon irradiation with a specific wavelength of light, the oligomerization domains bind each other and form a 'core', which also brings multiple IDRs close together because they are fused to the oligomerization domains. The recruitment of multiple IDRs effectively creates a new biopolymer with increased valency. This increased valency allows for the IDRs to form multivalent interactions and trigger LLPS. When the activation light is stopped, the oligomerization domains disassemble, causing the dissolution of the condensate.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.